Table 2.
Mean Fold-Change (95% Confidence Interval) From Baseline Over Time by Treatment Group
| Biomarker | Atazanavir/Ritonavir |
Raltegravir |
Darunavir/Ritonavir |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| N | Week 24 or 48 | N | Week 96 | N | Week 24 or 48 | N | Week 96 | N | Week 24 or 48 | N | Week 96 | |
| High-sensitivity C-reactive protein | 64 | 0.57 (0.40, 0.82) | 66 | 0.64 (0.46, 0.90) | 80 | 0.78 (0.59, 1.04) | 77 | 0.66 (0.51, 0.87) | 76 | 0.90 (0.69, 1.16) | 75 | 1.21 (0.91, 1.62) |
| IL-6 | 64 | 0.66 (0.52, 0.83) | 66 | 0.87 (0.69, 1.09) | 80 | 0.85 (0.67, 1.07) | 77 | 0.76 (0.65, 0.88) | 76 | 0.83 (0.67, 1.02) | 75 | 0.97 (0.78, 1.22) |
| D-dimer | 64 | 0.58 (0.42, 0.80) | 64 | 0.48 (0.35, 0.66) | 77 | 0.93 (0.72, 1.19) | 76 | 0.82 (0.65, 1.03) | 78 | 0.60 (0.44, 0.82) | 75 | 0.65 (0.48, 0.87) |
| GlycA | 67 | 0.89 (0.85, 0.93) | … | 79 | 0.90 (0.86, 0.94) | … | 78 | 0.91 (0.88, 0.94) | … | |||
| soluble CD14 | 63 | 1.00 (0.94, 1.06) | 65 | 0.96 (0.89, 1.04) | 80 | 0.91 (0.86, 0.96) | 77 | 0.89 (0.84, 0.94) | 75 | 1.00 (0.95, 1.05) | 74 | 0.96 (0.90, 1.03) |
| soluble CD163 | 61 | 0.56 (0.51, 0.61) | 62 | 0.50 (0.45, 0.56) | 76 | 0.59 (0.54, 0.64) | 73 | 0.55 (0.50, 0.61) | 71 | 0.61 (0.56, 0.67) | 70 | 0.58 (0.52, 0.65) |
| sIL-2r | 64 | 0.70 (0.61, 0.80) | 65 | 0.65 (0.58, 0.72) | 78 | 0.65 (0.58, 0.73) | 76 | 0.61 (0.54, 0.70) | 78 | 0.70 (0.62, 0.80) | 75 | 0.65 (0.57, 0.74) |
| %CD4+: CD38+HLADR+ | 58 | 0.47 (0.42, 0.53) | 61 | 0.33 (0.28, 0.39) | 65 | 0.53 (0.46, 0.62) | 70 | 0.38 (0.33, 0.45) | 73 | 0.53 (0.47, 0.61) | 72 | 0.36 (0.31, 0.42) |
| %CD8+: CD38+HLADR+ | 58 | 0.49 (0.44, 0.56) | 61 | 0.33 (0.29, 0.37) | 65 | 0.55 (0.50, 0.61) | 70 | 0.36 (0.30, 0.42) | 73 | 0.52 (0.47, 0.58) | 72 | 0.34 (0.29, 0.39) |
| %MNC: CD14(dim)CD16+ | 58 | 1.06 (0.99, 1.14) | 61 | 1.08 (1.00, 1.18) | 65 | 1.15 (1.05, 1.25) | 70 | 1.09 (1.01, 1.17) | 73 | 1.05 (0.99, 1.12) | 71 | 1.08 (1.00, 1.17) |
| %MNC: CD14+CD16+ | 58 | 0.58 (0.46, 0.72) | 61 | 0.58 (0.47, 0.70) | 65 | 0.93 (0.71, 1.23) | 70 | 0.85 (0.66, 1.10) | 73 | 0.78 (0.61, 1.02) | 71 | 0.71 (0.54, 0.93) |
GlycA was not assayed at week 96. N gives the number of participants with baseline and follow-up markers available for calculation of change.
Values in italics indicate statistically significant observations.
Abbreviations: HLADR, human leukocyte antigen DR; IL, interleukin; MNC, monocyte.